Liquid Biopsy for Early Cancer Detection and Monitoring Market

The liquid biopsy market consists of noninvasive diagnostic tools that detect cancer-related biomarkers in bodily fluids like blood for early detection and monitoring. The primary customers are diagnostic laboratories, hospitals, and physicians treating high-risk individuals or cancer patients. Key growth drivers include the high prevalence of cancer, increasing adoption of noninvasive diagnostic techniques, and technological advancements in next-generation sequencing (NGS) and AI-driven data analysis.